BC Extra | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
BC Innovations | May 6, 2019
Distillery Therapeutics

CAR Ts targeting PD-L1, FnEDB for three solid tumor types

DISEASE CATEGORY: Cancer INDICATION: Cervical cancer; colorectal cancer; melanoma Cell culture and mouse studies suggest CAR T cells targeting PD-L1 or FnEDB could help treat cervical cancer, colorectal cancer and melanoma. In a mouse-cell based...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
BC Innovations | Jul 10, 2017
Distillery Therapeutics


INDICATION: Cancer Mouse studies identified a chimeric IL-2 -Fc fusion protein that could help treat cancer. The fusion protein consisted of a human IL-2 variant containing three point mutations, linked to the Fc domain of...
BioCentury | Apr 27, 2015
Emerging Company Profile

Go-ing sugar specific

Go Therapeutics Inc. has developed a target discovery and screening platform that can generate mAbs against hybrid epitopes of cell surface proteins and aberrant O-linked glycosylation sites that are only found on tumors, resulting in...
BC Week In Review | May 9, 2005
Clinical News

AngioMab: Phase I halted

ASM halted development of AS1405 in order to transfer resources to its AS1411 aptamer that targets nucleolin . ASM will now attempt to out-license the compound. Antisoma plc (LSE:ASM), London, U.K.   Product: AngioMab (AS1405)  ...
BC Week In Review | Aug 2, 2004
Company News

Antisoma, Merck KGaA deal

ASM acquired from partner EMD Lexigen Research Center (Billerica, Mass.), a subsidiary of MRK, exclusive rights to BC1-IL12, a preclinical compound that ASM has renamed AS1409. AS1409 links ASM's huBC1 antibody with the IL-12 cytokine...
BC Extra | Jul 26, 2004
Company News

Antisoma acquires full rights to BC1-IL12

Antisoma (LSE:ASM; ASOM) acquired from partner EMD Lexigen Research Center (Billerica, Mass.) exclusive rights to BC1-IL12. Previously the partners shared co-development rights. The collaboration, which began in 2000, is no longer active. BC1-IL12 combines ASM's...
BC Week In Review | Nov 3, 1997
Company News

Cambridge Centre for Protein Engineering other research news

Cambridge Centre scientists and colleagues published in Nature Biotechnology the use of antibody fragments against the oncofetal isoform of fibronectin (B- FN ) to image cancer in vivo. B-FN is an extracellular matrix protein expressed in...
Items per page:
1 - 9 of 9